PE 22-28 vs Thymosin Alpha-1
Updated July 23, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of PE 22-28 and Thymosin Alpha-1 (also searched as Thymosin Alpha-1 vs PE 22-28) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
PE 22-28 centers on metabolic, while Thymosin Alpha-1 leans toward healing. On indexed research, PE 22-28 is ahead (PE 22-28: 5 studies, Human evidence; Thymosin Alpha-1: 5, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •PE 22-28 is strongest for metabolic; Thymosin Alpha-1 for healing.
- •Evidence: PE 22-28 Human evidence (5 studies) vs Thymosin Alpha-1 Human clinical (5).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
TREK-1 Channel Blocker | Shortened Spadin Analog
Synthetic Thymic Hormone | Immune System Modulator
PE 22-28 vs Thymosin Alpha-1: side-by-side
| Metric | PE 22-28 | Thymosin Alpha-1 |
|---|---|---|
| Class | Cognitive | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 5 | 5 |
| Research level | Emerging | Well Studied |
| Strongest effect | Metabolic & appetite | Healing & recovery |
| Healing & recovery | 2.0 | 4.0▲ |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 4.0▲ | 0.0 |
| Neuro & mood | 3.0▲ | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 2.0 | 4.0▲ |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | PE 22-28 | Thymosin Alpha-1 |
|---|---|---|
| Mechanism | — | Enhances T-cell function and promotes maturation of immune cells |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is PE 22-28?
### Summary PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.
Full PE 22-28 profile, mechanism & studies →What is Thymosin Alpha-1?
### Thymosin Alpha-1 Summary Thymosin Alpha-1 (Tα1) is a peptide that plays a crucial role in modulating immune responses and has been investigated for its potential therapeutic applications in various conditions, including infections and inflammatory diseases.
Full Thymosin Alpha-1 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Thymosin Alpha-1 | 4.0/5 effect signal |
| Metabolic | PE 22-28 | 4.0/5 effect signal |
| Neuro | PE 22-28 | 3.0/5 effect signal |
| Inflammation | Thymosin Alpha-1 | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack PE 22-28 and Thymosin Alpha-1?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
PE 22-28 vs Thymosin Alpha-1: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
PE 22-28 has 5 approved studies indexed (Human evidence), and Thymosin Alpha-1 has 5 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is PE 22-28 or Thymosin Alpha-1 better?
It depends on your goal. PE 22-28 is strongest for metabolic; Thymosin Alpha-1 for healing. PE 22-28 has more indexed studies (5). See the goal-by-goal breakdown above.
Is PE 22-28 or Thymosin Alpha-1 better for weight loss?
PE 22-28 shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Which has more research, PE 22-28 or Thymosin Alpha-1?
PE 22-28 has 5 approved studies indexed (Human evidence); Thymosin Alpha-1 has 5 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack PE 22-28 and Thymosin Alpha-1?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of PE 22-28 vs Thymosin Alpha-1?
PE 22-28: no community-reported effects logged yet. Thymosin Alpha-1: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is PE 22-28 or Thymosin Alpha-1 FDA-approved?
PE 22-28 is a research-use compound and is not FDA-approved. Thymosin Alpha-1 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Thymosin Alpha-1 better than PE 22-28?
For healing, Thymosin Alpha-1 has the edge; for metabolic, PE 22-28 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
PE 22-28 and Thymosin Alpha-1 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 23, 2026.